Fig. 5: Combining JAB1 inhibitors and chemotherapeutic drugs synergistically reverses drug resistance in breast cancer cells.
From: JAB1/CRL4B complex represses PPARG/ACSL5 expression to promote breast tumorigenesis
A, B In cells transfected with lentiviral Vector or FLAG-CUL4B, continuous doses of paclitaxel, docetaxel, gemcitabine, or CSN5i-3 were added, and the IC50 values of each drug were determined by CCK-8 assay. C Impact of combined CSN5i-3 and paclitaxel or docetaxel on MDA-MB-231 cells, presented as dose-response matrices and synergy score matrices. D, E In cells transfected with lentiviral Vector or FLAG-CUL4B, the lowest effective dose of CSN5i-3 was added along with varying doses of paclitaxel or docetaxel. The cells were then assayed using the CCK-8 test. F, G The clone formation assay was conducted in breast cancer cells transfected with either a lentiviral Vector or FLAG-CUL4B following treatment with the minimum effective dose of CSN5i-3 in combination with varying concentrations of paclitaxel or docetaxel. (A, B, D) The error bars indicate the mean ± SD derived from three separate experiments; two-tailed unpaired t-test; (F, G) two-way ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001.
